Loading quotes...

Forecast

The analysts' average price target is €138.07 (+12.51%). The median is €140.09 (+14.15%).

Buy
  16
Hold
  13
Sell
  0

  • Teleflex appoints Sean M. Salmon to board of directors

    Teleflex has appointed Sean M. Salmon, a former Medtronic executive with over 20 years of experience and most recently president of the Cardiovascular Portfolio, to its board of directors with immediate effect. The board will grow to nine members, eight of whom are independent, and Salmon will join the Growth and Operating Committee, which supports the company’s strategic transformation. Salmon has been the owner of Zamboni Holdings since December 2025 and brings experience from several leadership roles in the medical technology sector. » More on de.investing.com


  • Teleflex launches accelerated $250 million share buyback with Truist Bank

    Teleflex entered into an accelerated share repurchase (ASR) agreement with Truist Bank to buy back $250 million of shares; this is part of a previously announced $1 billion repurchase program. The $250 million payment is made on Monday; Truist will initially deliver shares worth 80% of that amount, and the final share count will be determined by the volume-weighted average price during the ASR term. The buyback is funded from proceeds of the OEM business sale and may be completed by Q4 2026; depending on settlement, Teleflex could receive additional shares or make further payments. Previously, Teleflex beat expectations for Q2 2026 on earnings and revenue but warned of a lower revenue outlook and ongoing integration delays in its interventional business. » More on de.investing.com


  • Teleflex sells OEM business for $1.5 billion to Montagu and Kohlberg

    Teleflex has completed the sale of its OEM business for $1.5 billion in cash and expects roughly $1.25 billion in net proceeds after taxes. The funds are to be used to repay $800 million of debt and to finish a $1 billion share buyback program. Teleflex will focus on its remaining medtech business areas and will publish an updated FY-2026 forecast when releasing its Q2 results. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics
In 2026, Teleflex has already paid €0.89 in dividends. The last payout was in September.

Financials

In the last quarter, Teleflex had revenue of €499.73m and net profit of €89.39m
(EUR) June 2026
YoY
Revenue 499.73m 24.95%
Gross profit 290.64m 20.94%
Net profit 89.39m 14.49%
EBITDA 107.69m 43.28%

Fundamentals

Metric Value
Market capitalization
€5.17bn
Number of shares
42.37m
52-week high/low
€129.79 - €89.67
Dividend yield
0.96%
Dividends TTM
€1.18
Beta
0.83
P/E ratio
-5.85
PEG ratio
-0.30
P/B ratio
2.04
P/S ratio
2.22

Company profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. The company also offers interventional products, which consists of various coronary catheters, structural heart therapies, and peripheral intervention and cardiac assist products that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded catheters, Guideline and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. It provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. The company also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; and respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings. It provides urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. The company was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.

Name
Teleflex
CEO
Jason Weidman
Headquarters Wayne, pa
USA
Website
Sector
Consumer Discretionary
Industry
Household Durables
IPO
17/03/1980
Employees 15,500

Ticker symbols

Exchange Symbol
NYSE
TFX
Frankfurt
TBH.F
Düsseldorf
TBH.DU
SIX
TBH.SW
München
TBH.MU
London
0ADI.L
🍪

Parqet  uses cookies. Learn more